Bupropion Sustained Release for Bereavement: Results of an Open Trial
J Clin Psychiatry 2001;62(4):227-230
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The present study was conducted to
assess whether DSM-IV-defined bereavement responds to bupropion
sustained release (SR).
Method: Twenty-two subjects who had lost their
spouses within the previous 6 to 8 weeks and who met DSM-IV
symptomatic/functional criteria for a major depressive episode
were evaluated. Subjects completed the Hamilton Rating Scale for
Depression (HAM-D), the Clinical Global Impressions scale, the
Texas Revised Inventory of Grief, and the Inventory of
Complicated Grief at baseline and follow-up. Subjects were
treated with bupropion SR, 150 to 300 mg/day, for 8 weeks.
Results: Improvement was noted in both
depression and grief intensity. For the intent-to-treat group,
59% experienced a reduction of >= 50% on HAM-D scores. The
correlations between changes in the HAM-D scores and the grief
scale scores were high, ranging from 0.61 (p = .006) to 0.44 (p =
Conclusion: Major depressive symptoms occurring
shortly after the loss of a loved one (i.e., bereavement) appear
to respond to bupropion SR. Treatment of these symptoms does not
intensify grief; rather, improvement in depression is associated
with decreases in grief intensity. The results of this study
challenge prevailing clinical wisdom that DSM-IV-defined
bereavement should not be treated. Larger, placebo-controlled
studies are indicated.